

J. B. Chemicals & Pharmaceuticals Limited

Regd. Office: Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Corporate Office: Cnergy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.

Phone: 022-2439 5200 / 2439 5500 Fax: 022 – 2431 5331/ 24131 5334

CIN: L24390MH1976PLC019380 Website: www.jbcpl.com E-mail: secretarial@jbcpl.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER 2016

(Rs. in lakhs)

SI.No.	Particulars	Quarter ended			Half Year ended	
		30-09-2016	30-06-2016	30-09-2015	30-09-2016	30-09-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Income from Operations					
	a. Net sales (inclusive of excise duty)	29,311.70	30,584.89	28,494.44	59,896.59	56,852.55
	b. Other Operating Income	837.06	843.87	607.15	1,680.93	1,113.07
	Total Income from Operations (a+b)	30,148.76	31,428.76	29,101.59	61,577.52	57,965.62
2	Expenses					
İ	a. Cost of materials consumed	9,791.71	9,555.32	9,819.75	19,347.03	18,842.73
	b. Purchases of stock-in-trade	2,311.71	2,135.01	2,003.69	4,446.72	4,312.79
	c. Excise Duty on sales	492.69	506.21	423.49	998.90	866.67
	d. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(691.02)	(174.06)	(189.50)	(865.08)	410.04
	e. Employees benefits expense	4,473.36	4,620.50	3,994.53	9,093.86	8,052.90
	f. Depreciation and amortization expense	1,118.33	1,131.67	1,004.00	2,250.00	1,981.00
	g. Exchange Fluctuation (Gain)/Loss	(31.49)	125.46	479.16	93.97	191.22
	h. Other Expenses	7,785.82	7,739.16	7,558.18	15,524.98	14,880.64
	Total Expenses	25,251.11	25,639.27	25,093.30	50,890.38	49,537.99
3	Profit from Operations before Other Income, Finance Cost (1-2)	4,897.65	5,789.49	4,008.29	10,687.14	8,427.63
4	Other Income	1,464.53	1,096.72	1,631.97	2,561.25	2,735.13
5	Profit before Finance Cost (3+4)	6,362.18	6,886.21	5,640.26	13,248.39	11,162.76
6	Finance Cost	203.30	77.88	335.22	281.18	533.05
7	Profit before Tax (5-6)	6,158.88	6,808.33	5,305.04	12,967.21	10,629.71
8	Tax expenses	1,638.92	1,822.83	1,090.26	3,461.75	2,451.15
9	Net Profit/(Loss) after Tax (7-8)	4,519.96	4,985.50	4,214.78	9,505.46	8,178.56
10	Other Comprehensive Income (net of Tax)	(8.07)	(8.07)	(7.75)	(16.14)	(15.49)
11	Total Comprehensive Income after Tax (9+10)	4,511.89	4,977.43	4,207.03	9,489.32	8,163.07
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.40	1,696.40	1,696.40	1,696.40
13	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)					
	(1) Basic	5.32	5.88	4.97	11.19	9.64
	(2) Diluted	5.32	5.88	4.97	11.19	9.64

NOTES

- 1 The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 18, 2016.
- The financial results for the quarter and half year ended on September 30, 2016 and September 30, 2015 have been prepared in accordance with new accounting standards prescribed under Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) applicable to the Company w.e.f. April 1, 2016.
- The auditors have carried out limited review of the above results for the quarter ended September 2016. Ind AS compliant financial results for quarter and half year ended September 30, 2015 have not been subjected to limited review. However, the management has exercised necessary due diligence to ensure that the financial results for the said period provide a true and fair view of the affairs of the Company.
- The reconciliation between net profit for the quarter and half year ended September 2015 reported earlier as per previous Indian GAAP and the one recast as above as per Ind AS is as under:

(Rs. in lakhs)

		(RS. IN Takns)
	Quarter ended September 30, 2015	Half year ended on September 30, 2015
Net profit reported for September 2015 as per previous Indian GAAP	4,898.53	8,326.72
Acturial loss on defined benefit plans reclassified to other comprehensive Income	11.85	23.69
Net gain/(loss) arising on fair valuation of Investments	(1,021.31)	(363.42)
Net gain/(loss) arising on fair Fair valuation of Forward Contracts	86.11	94.13
Others	(0.14)	13.59
Deferred Tax Impact on above Adjustments	239.74	83.85
Net Profit/(Loss) after Tax as per Ind AS	4,214.78	8,178.56

- 5 The Company has one reportable segment viz. Pharmaceuticals.
- 6 The figures for the previous period(s) have been re-grouped/restated, wherever necessary.
- 7 The statement of assets and liabilities as on September 30, 2016 is as under:

(Rs. in lakhs)

	Particulars	AS AT
Α	ASSETS	30-09-2016
1 A	Non-current assets	30 07 2010
	(a) Property, Plant and Equipment	37,577.33
	(b) Capital work-in-progress	17,608.32
	(c) Other Intangible assets	1,540.08
	(d) Financial Assets	1,010.00
	(i) Investments	33,506.47
	(ii) Loans	798.84
	(e) Other non-current assets	3,092.52
	TOTAL non current assets	94,123.56
2	Current assets	1 .,,
_	(a) Inventories	13,992.18
	(b) Financial Assets	
	(i) Investments	26,641.50
	(ii) Trade receivables	24,287.06
	(iii) Cash and cash equivalents	803.08
	(iv) Loans	7,133.71
	(c) Other current assets	1,436.82
	Total current assets	74,294.35
	Total Assets	1,68,417.91
В	EQUITY AND LIABILITIES	1
	Equity	
	(a) Equity Share Capital	1,696.40
	(b) Other Equity	1,29,139.26
	Total Equity	1,30,835.66
	LIABILITIES	
	Non-Current Liabilities	
	(a) Provisions	1,137.24
	(b) Deferred tax liabilities (Net)	4,649.01
	(c) Other non-current liabilities	415.74
	Total non current liabilities	6,201.99
	Current Liabilities	
	(a) Financial Liabilities	
	(i) Borrowings	11,864.15
	(ii) Trade payables	7,262.61
	(iii) Other financial liabilities	10,945.61
	(b) Other current liabilities	602.33
	(c) Provisions	705.56
	Total Current Liabilities	31,380.26
	Total Equity and Liabilities	1,68,417.91

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody Chairman & Managing Director

Place : Mumbai Date : 18/11/2016